$RPRX News

Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)

This Royalty Pharma Insider Reduced Their Stake By 10%

Royalty Pharma plc (RPRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?

Royalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare Conference

Royalty Pharma (RPRX) Valuation Check After Strong Share Price Momentum And Royalty Growth Potential

Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Royalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market Dominance

Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions

Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead

Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Income Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend Soon

10% Of This Royalty Pharma Insider's Holdings Were Sold

Royalty Pharma to present at upcoming investor conferences

Citigroup Maintains Buy on Royalty Pharma, Raises Price Target to $66

JP Morgan Maintains Overweight on Royalty Pharma, Raises Price Target to $58

Royalty Pharma Q1 Earnings Call Highlights

Royalty Pharma plc Q1 2026 Earnings Call Summary

Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?

Royalty Pharma (NASDAQ:RPRX) Beats Q1 Estimates and Raises Guidance, Fueling Strong Momentum